Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|May 18, 2023
- Pharmaceutical Technology's In the Lab eNewsletter, June 2023
- Volume 18
- Issue 6
ProBioGen Launches Lentivirus Packaging Cell Line
Author(s)Grant Playter
ProBioGen’s Lenti.RiGHT is a lentivirus production platform for use in gene transfer applications.
Advertisement
ProBioGen, a Berlin-based company specializing in the development and manufacture of APIs, announced its new lentivirus packaging cell line on May 17, 2023. Lenti.RiGHT is a lentivirus production platform based on human embryonic kidney 293 packaging cells.
According to a company press release, the new line is capable of producing lentiviral particles with titers between 107 and 108 transducing units per mL. It includes stable integration of gag-pol, rev, and vesicular stomatitis virus-G proteins.
"With our Lenti.RiGHT platform we have developed a new standard for efficient large-scale lentivirus production and CAR–T [chimeric antigen receptor T cell] manufacturing,” said Volker Sandig, chief scientific officer, ProBioGen, in the release. “It enables an inducible, scalable, and efficient production of high-titer lentiviral particles for gene transfer applications.”
Source:
Articles in this issue
over 3 years ago
Common Pitfalls in Data Integrityover 3 years ago
Dissolution’s Next Challenge–Nanoparticlesover 3 years ago
Astellas and Sony Enter ADC Platform Collaborationover 3 years ago
Agilent Releases New Vial Sampler Tray CapacityAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
What the Olanzapine Depot Approval Means for CMC Teams
4
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
5